证券代码：300391 证券简称：*ST长药 公告编号：2026-012 1 长江医药控股股份有限公司 关于公司股票可能被终止上市的第十二次风险提示公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、公司股票可能被实施交易类强制退市。2026年1月21日，长江医药控股 股份有限公司（以下简称"公司"或"长药控股"）股票收盘价格为0.64元/股， 已连续十五个交易日均低于1元；公司股票收盘市值2.24亿元，已连续九个交易 日均低于3亿元。根据《深圳证券交易所创业板股票上市规则》第10.2.1条的规 定，若公司出现连续二十个交易日的股票收盘价均低于1元，或者连续二十个交 易日的股票收盘市值均低于3亿元，公司股票将被终止上市。根据《深圳证券交 易所创业板股票上市规则》第10.7.1条的规定，若公司股票因触及交易类强制 退市规定被实施交易类强制退市，公司股票不进入退市整理期。 2、公司股票可能被实施财务类强制退市。公司股票自2025年4月22日起被 实施退市风险警示和其他风险警示，自2025年12月29日起被叠加实施退市风险 警示。鉴于公司未在2025 ...

公司预计2025年度期末净资产为负值，根据《深圳证券交易所创业板股票上市规则》第10.3.11条的规 定，公司股票可能被终止上市。敬请广大投资者注意投资风险。 1、本年度公司计提信用减值损失预计4亿元左右，其中，因本报告期货款回收较差，计提应收账款坏账 准备约3.4亿元左右。2、公司于2025年12月26日收到中国证券监督管理委员会下发的《行政处罚事先告 知书》。 格隆汇1月21日丨*ST长药(300391.SZ)公布，预计2025年亏损35,000万元–52,000万元，扣非亏损35,000万 元–52,000万元，营业收入12,000万元–17,000万元，归属于上市公司股东的所有者权益-60,000万 元–-90,000万元。 ...

证券代码：300391 证券简称：*ST 长药 公告编号：2026-014 1、业绩预告期间：2025年1月1日至2025年12月31日 2、业绩情形：预计净利润为负值、期末净资产为负值 3、业绩预告情况： 长江医药控股股份有限公司 2025 年度业绩预告暨公司将被终止上市的提示性公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 长江医药控股股份有限公司（以下简称"公司"）预计2025年度期末净资 产为负值，根据《深圳证券交易所创业板股票上市规则》第10.3.11条的规定， 公司股票可能被终止上市。敬请广大投资者注意投资风险。 一、本期业绩预计情况 三、业绩变动原因说明 1、本年度公司计提信用减值损失预计 4 亿元左右，其中，因本报告期货款 回收较差，计提应收账款坏账准备约 3.4 亿元左右。 2、公司于 2025 年 12 月 26 日收到中国证券监督管理委员会下发的《行政处 罚事先告知书》（以下简称"《告知书》"）。根据《告知书》认定的事实，公 司预计将对所有者权益进行相应调整： 上表中对所有者权益的预计调整金额是根据《告知书》初步测算的结果 ...

近日，*ST长药发布关于公司股票可能被终止上市的第十一次风险提示公告。公告显示，长江医药控股 股份有限公司股票可能因交易类、财务类及重大违法情形被终止上市。截至2026年1月20日，公司股价 已连续十四个交易日低于1元，市值连续八个交易日低于3亿元；2024年末净资产为负，2025年三季度末 净资产继续为负，且2021至2023年年度报告存在虚假记载，已被证监会立案并收到行政处罚事先告知 书。公司已多次发布相关风险提示。 最新公告列表 截至2026年1月21日收盘，*ST长药（300391）报收于0.64元，较前一交易日上涨20.75%，最新总市值为 2.24亿元。该股当日开盘0.59元，最高0.64元，最低0.55元，成交额达3217.33万元，换手率为14.83%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《关于公司股票可能被终止上市的第十一次风险提示公告》 ...

按最新收盘价计算，A股均价为14.68元，不足2元的个股共有33只，股价最低的是*ST长药，最新收盘 价为0.64元。 证券时报·数据宝统计显示，截至1月21日收盘，沪指报收4116.94点，A股平均股价为14.68元，从个股股 价分布看，高价股及低价股数量在A股市场总体占比相对较少。 低价股中，股价低于2元的共有33只，最低的是*ST长药，最新收盘价为0.64元，其次是*ST奥维、*ST 立方，最新收盘价分别为0.81元、0.96元。特征来看，股价低于2元个股中，共有8只ST股上榜，占比为 24.24%。 市场表现方面，上述低价股中，今日上涨的有10只，涨幅居前的有*ST长药、*ST立方、*ST金科，分别 上涨20.75%、20.00%、1.37%。下跌的有19只，跌幅居前的有东通退、*ST奥维、永泰能源，跌幅分别 为6.52%、4.71%、1.20%。（数据宝） 低价股排名 | 代码 | 简称 | 最新收盘价（元） | 日涨跌幅（%） | 日换手率（%） | 市净率（倍） | 行业 | | --- | --- | --- | --- | --- | --- | --- | | 300391 | *ST长药 ...

Core Viewpoint - *ST Changyao (300391) is facing multiple risks of being delisted, including trading-related, financial-related, and major violation-related delisting risks, as its stock price has been below 1 yuan for 15 consecutive trading days [2][5]. Group 1: Stock Performance - On January 21, *ST Changyao's stock opened at 0.64 yuan per share, reaching a daily limit increase for the second consecutive trading day [2]. - The stock has experienced a 20.75% increase, with a trading volume of 517,000 shares and a total transaction amount of 31.99 million yuan [3]. - The stock price has been below 1 yuan for 15 consecutive trading days, and if it remains below this threshold for the next 5 trading days, it will be suspended from trading [2][4]. Group 2: Delisting Risks - The company is at risk of trading-related delisting due to its stock price being below 1 yuan and market capitalization below 300 million yuan for consecutive trading days [4]. - Financial-related delisting risks arise from the expectation that the company's audited net assets will be negative by the end of 2025, along with potential adverse audit opinions on financial reports [5]. - Major violation-related delisting risks are present as the company is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data [5][6]. Group 3: Financial Irregularities - From 2021 to 2023, *ST Changyao's annual reports contained false records, inflating revenue by 215 million yuan, 284 million yuan, and 234 million yuan, which accounted for 9.12%, 17.57%, and 19.51% of the disclosed revenue respectively [6]. - The company also inflated total profit by 56.4 million yuan, 63.4 million yuan, and 43.7 million yuan during the same period, representing 35.62%, 88.23%, and 6.42% of the disclosed profit [6]. - Due to these financial discrepancies, the company may face major violation-related delisting if formal penalties are imposed [6].

Core Viewpoint - *ST Changyao is facing multiple risks of being delisted, including trading-related, financial-related, and major violation-related delisting risks, following its stock price falling below 1 yuan for 15 consecutive trading days [1][7]. Trading-Related Risks - The stock price of *ST Changyao opened at 0.64 yuan on January 21, after hitting the daily limit for the second consecutive day [1][7]. - The company has been under a trading risk warning since April 22, 2025, and if the stock price remains below 1 yuan for 20 consecutive trading days, it will be suspended from trading [8][10]. Financial-Related Risks - The company is at risk of financial-related delisting due to the possibility of having negative net assets at the end of the fiscal year 2025, as well as receiving audit reports with reserved opinions or negative opinions [3][9]. - As of January 20, the stock closed at 0.53 yuan, with a market capitalization of 186 million yuan, which has been below 300 million yuan for 8 consecutive trading days [8][10]. Major Violation-Related Risks - The company is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, with inflated revenues reported for 2021, 2022, and 2023 amounting to 215 million yuan, 284 million yuan, and 234 million yuan respectively [4][10]. - The inflated profits for the same years were reported as 56.4 million yuan, 63.4 million yuan, and 43.7 million yuan, representing significant percentages of the total disclosed profits [4][10].

Core Viewpoint - The A-share market is facing a wave of delisting risks as multiple companies report significant losses and fail to meet revenue standards, leading to potential ST (Special Treatment) designations and delisting warnings. Group 1: Company Performance and Financials - Tianjian Technology announced a net profit loss of 249.8 million yuan and revenue of only 142 million yuan for 2025, indicating a high likelihood of being subjected to ST delisting risk warnings after the annual report [1] - ST Aowei has seen its stock price drop to 0.89 yuan, with a total market value of only 309 million yuan, remaining below the 1 yuan face value for three consecutive trading days and below the 500 million yuan threshold for 12 days [3] - ST Changyao is facing severe challenges, with its stock price at 0.44 yuan and a total market value of 154 million yuan, marking it as the lowest in both price and market value in the A-share market [4] - ST Lifang reported a net profit loss of 62.2 million yuan for the first three quarters of 2025, with expectations of continued negative net profit for the full year [7] Group 2: Regulatory and Legal Issues - ST Changyao received a notice from the CSRC regarding administrative penalties for false reporting, with inflated revenues of 215 million yuan, 284 million yuan, and 234 million yuan over three years [6] - ST Lifang is under investigation for inflating revenues by 638 million yuan and costs by 628 million yuan through various fraudulent activities, facing potential fines totaling 40 million yuan for responsible parties [6] - Dongtong Tui has entered a delisting preparation period, with its stock price plummeting by 59.27% on the first trading day of this period due to false disclosures in annual reports from 2019 to 2022 [8]

Group 1 - The stock of *ST Changyao (300391) closed at 0.53 yuan on January 20, 2026, marking a 20.45% increase from the previous trading day, with a total market capitalization of 186 million yuan [1] - The stock has experienced a trading range between 0.44 yuan and 0.53 yuan on the same day, with a trading volume of 26.81 million yuan and a turnover rate of 15.09% [1] - Changjiang Pharmaceutical Holdings Co., Ltd. issued its tenth risk warning regarding the potential delisting of its stock, indicating that the stock price has been below 1 yuan for thirteen consecutive trading days and the market value has been below 300 million yuan for seven consecutive trading days [1] Group 2 - The company is projected to have negative net assets by the end of 2024 and is expected to continue this trend into 2025 [1] - The annual reports from 2021 to 2023 have been found to contain false records, leading to an investigation by the China Securities Regulatory Commission and the receipt of an administrative penalty notice [1] - The company faces significant risks including overdue debts, frozen bank accounts, and bankruptcy of subsidiaries [1]

证券代码：300391 证券简称：*ST长药 公告编号：2026-011 长江医药控股股份有限公司 关于公司股票可能被终止上市的第十一次风险提示公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、公司股票可能被实施交易类强制退市。2026年1月20日，长江医药控股 股份有限公司（以下简称"公司"或"长药控股"）股票收盘价格为0.53元/股， 已连续十四个交易日均低于1元；公司股票收盘市值1.86亿元，已连续八个交易 日均低于3亿元。根据《深圳证券交易所创业板股票上市规则》第10.2.1条的规 定，若公司出现连续二十个交易日的股票收盘价均低于1元，或者连续二十个交 易日的股票收盘市值均低于3亿元，公司股票将被终止上市。根据《深圳证券交 易所创业板股票上市规则》第10.7.1条的规定，若公司股票因触及交易类强制 退市规定被实施交易类强制退市，公司股票不进入退市整理期。 2、公司股票可能被实施财务类强制退市。公司股票自2025年4月22日起被 实施退市风险警示和其他风险警示，自2025年12月29日起被叠加实施退市风险 警示。鉴于公司未在2025年1 ...